manilatimes11h
Alector Announces Results from AL002 INVOKE-2 Phase 2 Trial in Individuals with Early Alzheimer's Disease and Provides Business Update
As of September 30, 2024, Alector has $457.2 million in cash, cash equivalents, and investments, which the company continues ...
STAT9h
Alector Therapeutics’ novel Alzheimer’s strategy fails in Phase 2 trial
Alector Therapeutics, working with AbbVie, was testing whether modulating immune cells in brain would slow Alzheimer's ...
Alector Plummets After Alzheimer's Drug Trial Fails Primary Endpoint
Shares of Alector tumbled in after-hours trading after the company said its Alzheimer drug candidate, AL002, failed to meet its phase 2 primary endpoint of slowing clinical progression of the disease.
ENDPOINTS NEWS9h
Alec­tor says Alzheimer's pro­gram tar­get­ing mi­croglia fails Phase 2, stock dives
Alec­tor re­port­ed a Phase 2 fail­ure for an Ab­b­Vie-part­nered Alzheimer’s pro­gram Mon­day af­ter­noon and said it will ...